Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Trials ; 24(1): 758, 2023 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-38012733

RESUMO

BACKGROUND: Amiodarone and esmolol can help to prevent and treat post-cardiac surgery reperfusion ventricular fibrillation. However, the relative efficacies of these two drugs remain unknown. The aim of the current trial is to compare the performances of amiodarone and esmolol for preventing reperfusion ventricular fibrillation following open heart surgery. METHODS/DESIGN: This is a single-center, prospective, double-blind, controlled clinical trial. A total of 260 patients undergoing heart valve or aortic surgery will be assigned randomly to treatment with prophylactic esmolol (intervention group) or amiodarone (control group). The main outcome is the incidence of reperfusion ventricular fibrillation following aortic opening during extracorporeal circulation. The secondary outcomes are the rate of automatic cardiac resuscitation, energy and frequency of electrical defibrillation, number of electrical defibrillations, and pacemaker use in the two groups of patients. Information on the patients' general condition and the durations of anesthesia, extracorporeal circulation, aortic occlusion, and operation time will be recorded. We will also compare the heart rate, mean arterial pressure, and central venous pressure between the two groups of patients at induction of anesthesia (T1), start of surgery (T2), start of extracorporeal circulation (T3), aortic block (T4), aortic opening (T5), after opening for 10 (T6), 20 (T7), and 30 min (T8), at cessation of extracorporeal circulation (T9), and at the end of surgery (T10) and compare blood gas analysis results at T1, T5, T9, and T10. DISCUSSION: This study will determine if prophylactic esmolol is more effective than amiodarone for reducing the incidence of reperfusion ventricular fibrillation in patients undergoing heart valve or aortic surgery. TRIAL REGISTRATION: China Clinical Trials Registry ChiCTR1900026429. Registered on 2019.10.9.


Assuntos
Amiodarona , Humanos , Amiodarona/efeitos adversos , Fibrilação Ventricular/diagnóstico , Fibrilação Ventricular/etiologia , Fibrilação Ventricular/prevenção & controle , Estudos Prospectivos , Reperfusão/efeitos adversos , Valvas Cardíacas , Ensaios Clínicos Controlados Aleatórios como Assunto
2.
Trials ; 24(1): 741, 2023 Nov 18.
Artigo em Inglês | MEDLINE | ID: mdl-37980486

RESUMO

BACKGROUND: Both acute normovolumic hemodilution (ANH) and autologous platelet-rich plasma (aPRP) have been demonstrated blood-protective effects in cardiac aortic surgery; however, the efficacies of the two methods have not been compared. This study aims to compare the effects of aPRP and ANH prior to aortic surgery on postoperative bleed and other outcomes. METHODS AND ANALYSIS: This is a prospective, single-center, double-blind controlled clinical trial including 160 patients randomized 1:1 to receive aPRP (test group) or autologous whole blood (ANH, control group). The primary objective is to compare the drainage volumes in the two groups at 24, 48, and 72 h postoperatively. Secondary outcomes include input of allogeneic blood and blood products and durations of aortic block, extracorporeal circulation, deep hypothermic arrest of circulation, tracheal extubation, hospital stay, requirement for secondary surgical hemostasis, and application of intra-aortic balloon pump or extracorporeal membrane oxygenation in the two groups. In addition, heart rate, systolic blood pressure, diastolic blood pressure, central venous pressure, and thromboelastography recorded before blood reservation (T1), after blood reservation (T2), before blood transfusion (T3), and after the blood is returned (T4) to the transfusion will be compared between the two groups of patients. DISCUSSION: This study will demonstrate if the use of aPRP could reduce the risk of bleeding after aortic surgery compared with ANH. The results are expected to have practical clinical applications in terms of more effective blood protection and shorter hospital stay. TRIAL REGISTRATION: This study was registered with the Chinese Clinical Trial Registry ( http://www.chictr.org.cn/ ) with the ID ChiCTR 1900023351.Registered on May 23, 2019. TRIAL STATUS: Recruiting start date: July 1, 2019; expected recruiting end date: July 1, 2024 Version number and date: Version 2 of 05-04-2019.


Assuntos
Hemodiluição , Plasma Rico em Plaquetas , Humanos , Hemodiluição/efeitos adversos , Hemodiluição/métodos , Estudos Prospectivos , Transfusão de Sangue/métodos , Preservação de Sangue , Ensaios Clínicos Controlados Aleatórios como Assunto
3.
Space Med Med Eng (Beijing) ; 18(1): 25-7, 2005 Feb.
Artigo em Chinês | MEDLINE | ID: mdl-15852537

RESUMO

OBJECTIVE: To investigate the changes of the expression of heat shock protein 70 (HSP70) in the cochlea of guinea pigs under acute hypoxia. METHOD: Different degrees of acute hypoxia were imposed on guinea pigs and slices of the cochlea were examined by immunohistochemistry to detect HSP70. RESULT: In normal situation, HSP70 is expressed in guinea pig's cochlea, especially in spiral ganglion and Corti's organ, under acute hypoxia, this expression was strengthened, and the degree of this strengthening showed no correlation with degree of hypoxia. CONCLUSION: These results suggest that acute hypoxia can strengthen the expression of HSP70 in guinea pig's cochlea, and the degree of hypoxia has no effects on the degree of this strengthening. The expression of HSP70 in the cochlea may be a kind of protection to the structure and the function of the inner ear.


Assuntos
Cóclea/metabolismo , Proteínas de Choque Térmico HSP70/biossíntese , Hipóxia , Animais , Expressão Gênica , Cobaias , Proteínas de Choque Térmico HSP70/genética , Ratos , Gânglio Espiral da Cóclea/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...